It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...

Tempus AI acquires Paige in an $81.25 million deal, adding FDA-cleared cancer detection tools and a dataset of 7 million ...

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus is acquiring Paige for $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus' assumption of Paige's remaining commitment under its existing Microsoft Azure ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 performance. Read more here.

After performing well in the first several weeks of 2025, Tempus AI stock hit a high-water mark and closed at $89.44 on Feb. 14, representing a 124% gain over its opening price.